Skip to main content
. Author manuscript; available in PMC: 2020 Apr 1.
Published in final edited form as: Arthritis Rheumatol. 2019 Mar 5;71(4):632–640. doi: 10.1002/art.40773

Figure 3. Protocol of PLGA NP administration for the identification of an optimal dose for the expansion of Tregs in vivo.

Figure 3.

Comparison of anti-CD2/4 Ab-coated NPs with NPs coated with anti-CD2 and anti-CD4 Ab alone, or in combination. A. Percentages of CD4+ Tregs (top) and CD8+ Tregs (bottom) in mice treated according to protocol (A) indicated in the figure quadrant. B. Percentages of CD4+ Tregs (top) and CD8+ Tregs (bottom) in mice treated according to protocol (B) indicated in the figure quadrant. Representative of two experiments with four mice per group; *P<0.05 by Mann Whitney U test comparisons with control.

HHS Vulnerability Disclosure